PUBLISHER: Allied Market Research | PRODUCT CODE: 1108565
PUBLISHER: Allied Market Research | PRODUCT CODE: 1108565
The global newborn screening market valued at $ 1,055.24 million in 2021, and is projected to reach $ 2,038.47 million by 2031, registering a CAGR of 6.8% from 2022 to 2031
Newborn screening test is the series of test performed during the first few days of your baby's life, usually by a hospital health care practitioner. A few drops of blood from a heel prick are placed on a special card, called a Guthrie card. this card, along with your baby's details, is mailed to a specialized state laboratory, which will test the blood sample for a variety of health disorders, including CF (cystic fibrosis). Newborn screening in certain states requires two blood samples, one at birth and the other a few weeks later. Newborn screening is essential for detection and early diagnosis of certain genetic, endocrine, and metabolic disorders, and are also tested for hearing loss and critical congenital heart defects (CCHDs).
The major factors that drive the growth of the global newborn screening market include increasing government support for newborn screening and development in screening technology. In addition, high birth rate and increasing incidence of neonatal disease propel the market growth. However, lack of improvement in healthcare infrastructure. Conversely, screening of genetic disorders and emerging market such as Brazil, China and India provide significant opportunities to key players in this market due to increase in birth rates and rise in disposable income.
The global newborn screening market is segmented into test type, technology , product type and region. According to test type, the market is categorized into blood test, hearing screening test, heart screening test. By technology, it is segregated into tandem mass spectrometry (TMS), molecular assay, immunoassays & enzymatic assays, hearing screen technology, pulse oximetry screening technology and others(DNA based assay and electrophoresis). on the basis of end user, the market is bifurcated into hospitals and clinical laboratories. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include: the Ab Sciex LLC (subsidiary of Danaher Corporation), Perkinelmer, Inc., Waters Corporation, Natus Medical Incorporated, Masimo Corporation, Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Covidien Plc, Ge Healthcare (subsidiary of General Electric Company) and Trivitron Healthcare.
Key Benefits For Stakeholders
By Product Type
By Test Type
By Technology
By End User
By Region